- Recommended for dogs diagnosed with congestive heart failure (CHF)⁴ due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM).
- According to published studies, helps extend the survival time and improve the quality of life in dogs with heart failure¹,².
- Available as a highly palatable, beef-flavored chewable tablet in 4 convenient dosing sizes (1.25 mg, 2.5 mg, 5 mg, and 10 mg) for small, medium, large, and extra-large dogs.
- Prescription required
- Manufactured by Boehringer Ingelheim
Product description
For the heart from the start
Did you know that 10% of all dogs presented to primary care in the US suffer from heart disease?¹ Usually they’re affected by one of two conditions—myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM)—both of which may progress to congestive heart failure (CHF). As dogs age, their risk increases, but there are treatments that can help.
Talk to your vet about VETMEDIN (pimobendan) Chewable Tablets or VETMEDIN Solution (pimobendan oral solution) to manage clinical signs and symptoms in dogs that have progressed to CHF due to MMVD or DCM. Based on studies, VETMEDIN Chewable Tablets or VETMEDIN Solution help dogs survive longer and have an improved quality of life.²,³
Important Safety Information: VETMEDIN (pimobendan) Chewable Tablets and VETMEDIN Solution (pimobendan oral solution) are for use in dogs with clinical evidence of heart failure only. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. For more information, see full prescribing information for Chewable Tablets, or full prescribing information for Solution.
References:
1. Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019;33:1127-1140. https ://doi.org/10.1111/jvim.15488
2. Lombard CW, Jöns O, Bussadori CMI; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249-261.
3. VETMEDIN (pimobendan) Chewable Tablets [Freedom of Information Summary]. St. Joseph, MO; Boehringer Ingelheim Vetmedica, Inc., 2022.
VETMEDIN is a registered trade mark of Boehringer Ingelheim Vetmedica GmbH, used under license. All other trade marks are property of their respective owners. 2025 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0921-2024.